Address: BSI Building 13th Floor 389 Chiswick High Road London W44AL UK
Tel: +44 208 987 3333
Web: http://www.actelion.com/en/index.page
Actelion is a biopharmaceutical company focused on the discovery, development and commercialization of smallmolecule drugs as innovative treatments to serve high unmet medical needs. The company has proven its ability to discover new compounds and to rapidly move them from research through development to commercialization.
The company has its corporate headquarters in Allschwil/Basel, Switzerland where it was founded in 1997. Its shares have been listed on the SIX Swiss Exchange since 2000.
Tracleer®
Veletri®
Ventavis®
Zavesca®
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
Ben Ellis, general manager at Lupin UK and Ireland, talks about the strategic challenges of transitioning from the sphere of generics to specialist pharma and how he hopes Lupin can…
Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to…
Aisling Burnand, CEO of the Association of Medical Research Charities (AMRC), shares the organization’s vision and the significant contributions of its member charities to the life sciences R&D ecosystem in…
Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and…
See our Cookie Privacy Policy Here
